Hansa Biopharma half year report 2022
• Continued solid sales in Q2• Positive NICE recommendation obtained • Completed enrollment in imlifidase Phase 2 program in AMR • Peter Nicklin elected as new Chairman of the Board of DirectorsLund, Sweden July 19, 2022, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January to June 2022. Highlights for the second quarter 2022 · Continued solid sales in the second quarter with SEK 19.5m in product sales; total revenue amounted to SEK 26.4m. · On June